Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SQAP
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**SQAP** is a drug code name that appears in biomedical literature in the context of research but does not correspond to an approved pharmaceutical, biosimilar, or generic product. SQAP most commonly refers to *sulfoquinovosyl acylpropanediol*, a synthetic analog of sulfoquinovosyl diacylglycerols, which are natural sulfolipids found in membranes of plants and some bacteria. In preclinical research, SQAP acts as an **anti-tumor agent** and is thought to improve oxygen delivery or modify the tumor microenvironment by altering vascular permeability. Its mechanism may involve *extracellular matrix interaction*, *modulation of oxygen transport*, or targeting *hypoxia signaling* pathways, though exact molecular targets are not fully elucidated. SQAP has been mainly explored for **oncology** (cancer) indications. It is not an approved pharmaceutical, and no specific developer or manufacturer is listed in authoritative sources.
- Brand names
- SQAP
- Other names
- SQAP
02
Targets
FAK (Focal adhesion kinase)HSD17B4 (17-beta-hydroxysteroid dehydrogenase type 4)PARG (Poly(ADP-ribose) glycohydrolase)PARP1 (Poly (adp-ribose) polymerase 1)ADRM1 (Proteasome regulatory particle subunit RPN13)SCP2 (Sterol carrier protein 2)TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on SQAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQAP.